Tumor Volume Data

Group Day Mouse 1 Mouse 1 Mouse 2 Mouse 2 Mouse 3 Mouse 3 Mouse 4 Mouse 4 

Group Day Weight Volume Weight Volume Weight Volume  

Group Day Mouse 8 Mouse 8 Mouse 9 Mouse 9 Mouse 10 Mouse 10 Mouse 11 Mouse 11 

---

Raloxifene, a more complete uterine antagonist than tamoxifen or clomiphene, significantly reduces leiomyoma size in post-menopausal women [31], yet it is less efficacious at reducing tumor volume in pre-menopausal women [32], This result has been attributed to the poor pharmacokinetic properties of this compound in which extensive conjugative metabolism of the phenol(s) limits the circulating levels of the parent drug. In addition, clinical outcomes in premenopausal women treated with raloxifene suggest that this compound, like tamoxifen and clomiphene, can affect the ovaries via the HPO axis [33]. These data, taken collectively, indicate that current SERMs lack the efficacy, pharmacokinetic, and ovarian safety properties needed to treat leiomyoma in ovulatory women. 

For example for Walker carcinosarcoma the data on growth of tumor volume V are well described by Gompertz equation ... 

Same as for prognosis. The data are not good enough for accurate staging unless the value is reflecting tumor volume. 

Now, returning to the questions posed by the researchers. When analysis of variance was done on Day 33 data only, the p-value for treatment group was 0.1587. Thus, there was no apparent difference in mean tumor volumes among treatments nor was there a difference between IP and PO administration of Drug X. Basically, Drug X could not be distinguished from placebo at the doses given despite the apparent difference in... 

Bentzen SM, Thames HD (1996) Tumor volume and local control probability clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 36(1 ) 247-251... 

A reverse-phase HPLC method with ESI-MS detection to characterize the pharmacokinetic behavior of procarbazine, a cytotoxic chemotherapeutic agent used in the treatment of lymphomas and hrain tumors. The data are used in a phase I trial concentrations are measured in human plasma. The calibration curve is linear in the 0.5-50 ng/ml concentration range. Average recovery rate 102.9%. Lower limit of quantitation 0.5 ng/ml accmacy 105.2% interday precision 3.6% RSD sample volume 150 p,l. Interday precisions at widely different concentrations 97-98%. The stability of the drug under storage and sample preparation conditions have also been thoroughly tested. Sensitivity is sufficient for monitoring plasma levels after oral administration. 

Fig. 8. Drug-induced proteome changes predict for therapeutic resistance. (A) Mice bearing established >300 mm Fo5 (Flerceptin-resistant) and 1282 (Flerceptin-sensitive) tumors were treated with Flerceptin 30 mg/kg i.p. twice a week. Each data point represents mean tumor volume SD (Fo5, = 3 1282, n = 6). (B) Fo5 and 1282 tumors of equivalent size were harvested 24 and 48 h after a single dose of Herceptin i.p. and subjected to mass spectral proteomic profiling analysis. An example of a statistically significant change observed after Herceptin treatment in the 1282 tumors not observed in the Fo5 tumors is shown. The solid line trace (—) represents control, untreated tumors while the dotted line trace ( ) represents Herceptin-treated tumors. (Reprinted with permission from the American Association for Cancer Research from Cancer Research 64 9093-9100, 2004.)...

---